Cambria Pharmaceuticals Announces $5.4 Million Series A Financing.Capital to be Used to Advance Discovery of Breakthrough Medicines for Serious Neurological Disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). WOBURN, Mass. -- Cambria Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has closed a $5.4 million Series A financing. Participating investors included Biogen Idec New Ventures, CommonAngels, and a number of individual investors. "We believe that this Series A funding is a validation of Cambria's novel approach to identifying new therapeutics for high-profile neurological diseases for which there is a clear unmet need. This investment will be used, along with a comparable amount of venture philanthropy funding that we have previously obtained, to advance our lead program in ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. , as well as drug discovery efforts for other serious neurological disorders," stated Leo Leo, in astronomy Leo [Lat.,=the lion], northern constellation lying S of Ursa Major and on the ecliptic (apparent path of the sun through the heavens) between Cancer and Virgo; it is one of the constellations of the zodiac. Liu, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . In addition, the Company has incorporated in Delaware and changed its name to Cambria Pharmaceuticals, Inc. from Cambria Biosciences LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control to reflect its strategic focus on discovering first-in-class, disease-modifying small molecules to address neurological disorders. A new Board of Directors will be constituted in concert with this corporate conversion. About Cambria Pharmaceuticals Cambria Pharmaceuticals is focused on the discovery of innovative treatments for serious and progressively disabling neurological disorders. The Company exploits recent discoveries in the genetic basis of these disorders to engineer novel disease models and identify first-in-class, disease-modifying compounds. Cambria leverages collaborative relationships with academic institutions and patient-focused foundations to advance its programs in ALS (Lou Gehrig's disease Lou Geh·rig's disease n. See amyotrophic lateral sclerosis. ) and other serious neurological diseases. www.cambriapharma.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion